Catalyst Wire Dossier Catalyst Wire Dossier

TIVDAK

tisotumab vedotin · Seagen Inc.
Drug timelines are a Plus or Pro feature.

9 regulatory and trial events tracked for TIVDAK, covering 2021-09-20 to 2026-06-05. Get the full timeline:

Most recent: EMA Authorised: Tivdak (tisotumab vedotin) — Genmab A/S

See pricing